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A bstract
Sudden cardiac death (SCD) in young athletes is generally caused by inherited cardiac disorders. While these events are relatively few 
compared to other cardiac deaths, they are tragic in that death occurs in a young, otherwise healthy person. The genetic abnormalities most 
associated with SCD are hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, long QT syndrome, Brugada 
syndrome, and catecholaminergic polymorphic ventricular tachycardia. As a result of growing awareness that these deaths can be prevented, 
guidelines have been issued in both Europe and the United States to help screen and determine qualification for young persons who want to 
participate in competitive athletics. There remains debate on the how extensive screening should be, in particular over the use of the 12-lead 
electrocardiogram (ECG), with European guidelines mandating ECG and United States guidelines not recommending routine use of the ECG. 
(Anadolu Kardiyol Derg 2009; 9: Suppl 2; 17-23)
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Geng atletlerde ani kalp oliimiine genellikle, kalitsal kalp hastaliklari sebep olmaktadir. Bu olaylar, diger kardiyak oliimlerle kiyaslandiginda 
nispeten az olsa da saglikli bir gengteki bu olum trajiktir. Ani kalp oliimii ile beraber en gok goriilen genetik anormallikler, hipertrofik kardiyomi- 
yopati, aritmojenik sag ventrikiiler kardiyomiyopati, uzun QT sendromu, Brugada sendromu ve katekolaminerjik polimorfik ventrikiiler tagikardi- 
dir. Bu oliimlerin onlenebilirligi konusunda farkindaligin artmasi sonucu hem Avrupa, hem de Birlegik Devletlerde yari§maci atlet olmak isteyen 
gengler igin tarama ve niteliktespitine yardimci olan kilavuzlar yayinlandi. Kapsamli taramanm nasil olacagi, ozellikle 12 derivasyonlu elektro- 
kardiyografi (EKG) kullammi iizerine, Avrupali kilavuzlar EKG'yi zorunlu kilarken, Amerikali kilavuzlarin rutin EKG kullanimini tavsiye etmemesi 
halen tarti§ilmaktadir. (Anadolu Kardiyol Derg 2009; 9:0zelSayi2; 17-23)
Anahtar kelimeler: Atlet, ani kardiyak olum, hipertrofik kardiyomiyopati, iyon kanalopatiler, aritmojenik ventrikul kardiyomiyopatisi
Introduction
Sudden cardiac death (SCD) of a young (under age 35) ath­
lete is a catastrophic event not only because very often these 
tragedies occur in the public eye, but also because athletes are 
young, and considered among the healthiest members of our 
society. The true incidence of SCD in young athletes is not 
known with certainty. In the U.S. it has been reported as 
1:200,000 young athletes per year in Minnesota high schools (1).
In contrast, a prospective study in the Veneto region of Italy 
reported an incidence of SCD of 2.1 per 100,000 athletes per year 
from cardiovascular diseases (2). The most common causes are 
inherited cardiovascular disorders. In the United States, hyper­
trophic cardiomyopathy (HCM) accounts for 36% of the total 
deaths, followed by congenital coronary artery anomalies, 17%. 
Arrhythmogenic right ventricular cardiomyopathy (ARVC) and 
ion channelopathies represent 4% and 3% of the total deaths 
respectively (3,4). In Europe, specifically in the Veneto region of
Address for Correspondence/Yazi§ma Adresi: Mark V. Sherrid, MD, St. Luke’s-Roosevelt Hospital Center 100010th Avenue New York City, NY 10019 Phone: +1 212 523
7370 Fax: +1 212 523 7370 E-mail: MSherrid@chpnet.org 
©TelifHakki 2009AVES Yaymcilik Ltd. §ti. - Makale metnine www.anakarder.com web sayfasmdan ula§ilabilir.
©Copyright2009 by AVES Yaymcilik Ltd. - Available on-line at www.anakarder.com
Wever-Pinzon et al.
Sudden cardiac death in athletes
Anadolu Kardiyol Derg
2009; 9: Suppl 2; 17-23
Italy, the most common cause of SCD in athletes is ARVC, 
accounting for 22% of the total deaths, followed by anomalous 
origin of coronary arteries with 12%. In contrast with the U.S. 
experience, HCM was the cause of SCD in only 2% of the young 
athletes (5). Although the reasons for this difference are unclear, 
it may be due to the early detection of HCM by the Italian 
national pre-participation screening program. Italy is the only 
country worldwide where, since 1982, pre-participation screen­
ing is required by law. The Italian guidelines mandate use of the 
12-lead electrocardiogram (ECG) in addition to history (personal 
and family) and physical examination. Another possible expla­
nation is that Italy is a more homogeneous population compared 
to the United States and hence may have less genetic variation.
Though the incidence of SCD in athletes is low, many support 
specific screening protocols to detect genetic heart disease 
prior to athletic participation. In Italy, mandated screening has 
been reported to significantly reduce SCD in competitive athletes
(11). In 2005, the European Society of Cardiology (ESC) released 
a consensus document recommending the use of ECG in addition 
to history and physical examination (5). In 2007, the American 
Heart Association (AHA) released an update to the 1996 
recommendations for pre-participation screening, leaving 
unchanged the recommendations of using only history and 
physical examination for screening. This last recommendation 
was based on the large number of athletes eligible for screening 
(10 million individuals), the apparent low prevalence of SCD in 
this group, and lack of trained personnel and funds that would be 
required. The AHA statement also concluded that implementation 
of expanded screening including ECG, would not be not cost 
effective for the U.S (4). There is concern about the specificity of 
ECG abnormalities and the possibility that sports participation 
might be proscribed in individuals with normal variant ECGs. 
There is often substantial emotional distress associated with the 
recommendation of non-participation. This must be carefully 
weighed against the very real and mortal danger of competing 
with inherited cardiac disease.
This article will review the genetic cardiovascular disorders 
that are most commonly associated with SCD in young 
competitive athletes and will discuss current recommendations 
for disqualification from participation in competitive athletics.
This review will focus on the inherited causes of ventricular 
fibrillation and will not cover Marfan's syndrome an inherited cause 
of sudden death, but because of aortic rupture or dissection.
Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy is a familial cardiac disease 
with a heterogeneous genotypic and phenotypic expression, 
complex pathophysiology and treatment options. It is inherited 
as an autosomal dominant trait; and is the most common 
inherited cardiac disorder, occurring in 1:500 of the general 
population (6). About 50% of the individuals with HCM will have 
a relative with the disease. Those without a family history may 
have sporadic mutations. Approximately 50% of patients with 
HCM are found on genotype analysis to have a sarcomeric 
disease-causing mutation. Sarcomeric mutations of >11 genes
that code for myofilaments or their supporting proteins have 
been identified with with myosin-binding protein C and beta- 
myosin heavy chain being the most common mutations. Even 
though the bulk of genetically determined HCM occurs in 8 
genes, >1000 HCM-causing mutations are dispersed over many 
loci of these genes. These different mutations cause varying 
phenotypic expression, clinical course, and prognosis. Because 
there are so many mutations, and because many families have 
"private mutations" that have been infrequently or never 
reported elsewhere, there are no gene-specific prognostic 
features. However, genotype positive HCM has a worse 
prognosis than genotype negative HCM, with greater occurrence 
of the combined endpoints of cardiac death and disability.
Clinical presentation
The clinical detection of athletes with HCM can be 
challenging, given that many athletes may present with the 
nonobstructive form, which can make the disease clinically 
silent. Hypertrophic cardiomyopathy should be suspected in a 
young athlete who presents with exertional dyspnea, chest pain, 
unexplained syncope or prior recognition of a heart murmur. 
Dyspnea usually is caused by inability to increase cardiac 
output and left ventricular (LV) filling pressures due to the non 
compliant hypertrophied LV, and exacerbated by decreased 
filling time. It is now apparent that obstruction is frequently 
provocable in non-obstructive HCM after exercise. Angina may 
occur secondary to subendocardial ischemia caused by luminal 
narrowing of the intramural coronary arteries and, in patients 
with obstruction, by supply-demand mismatch. Syncope can 
occur either due to LV outflow tract obstruction resulting in 
decreased cardiac output leading to cerebral hypoperfusion or 
due to cardiac arrhythmias. Histopathologic myocardial fibrosis 
or myocyte fiber disarray is believed to be the substrate for 
malignant ventricular arrhythmias and may be triggered by 
ischemia or local abnormality in electrolyte concentration.
A family history of HCM, sudden cardiac death, heart 
disease in a close relative <50 years of age or unexplained 
syncope should also raise the suspicion for HCM. On the 
physical examination, the most important finding is a systolic 
murmur increased/elicited by provocative maneuvers such as 
Valsalva, standing or exertion.
Electrocardiographic abnormalities can be found in 75-95% 
of HCM patients and may precede the appearance of overt 
hypertrophy (8). Typical electrocardiographic abnormalities 
include: increased precordial voltages consistent with left 
ventricular hypertrophy (LVH), ST segment and T wave 
abnormalities, abnormally deep Q waves in inferior and lateral 
leads and ventricular or supraventricular arrhythmias such as 
atrial fibrillation, premature ventricular contractions and 
ventricular tachycardia can be present (9).
Echocardiographic findings
Echocardiography is the most important imaging technique in 
the evaluation of suspected HCM. HCM is diagnosed when LV
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hypertrophy occurs in the absence of a clinical condition that 
would cause hypertrophy. Asymmetric wall thickness >15 mm 
with a small LV cavity (<45mm) is diagnostic. Symptomatic 
patients most often present with wall thicknesses between 
20-30 mm, but the degree of wall thickening can vary widely. 
Typically, the LV hypertrophy involves the septum in a greater 
degree, but the phenotypical presentation of the disease is 
diverse, with mid and apical HCM being other variants of the 
disorder. Other echocardiographic changes indicative of HCM 
include reduced early mitral annulartissue Doppler velocity (Ea) 
due to decreased relaxation in early diastole, systolic anterior 
motion (SAM) of the mitral valve and a late peaking systolic 
pressure gradient in the LV outflow tract. Diagnosis in some 
patients may require use of echocardiogram with intravenous 
contrast (apical HCM) or cardiac magnetic resonance (CMR) 
imaging.
Asymptomatic individuals who present with LV wall thickness 
between 13 and 15 mm represent a diagnostic dilemma and 
should be carefully evaluated and differentiated from athlete's 
hearts, benign left ventricular hypertrophy due to vigorous 
training. Athlete's heart, the benign condition does not occur in 
casual athletes; rather it occurs in elite athletes, in training for 
higher levels of competition. In patients with wall thickness 
between 13 and 15 mm, a relatively small left ventricle, 
asymmetric hypertrophy, SAM, impaired relaxation on tissue 
Doppler imaging, or decreased aerobic capacity on metabolic 
stress testing suggest HCM. In some patients with vexing 
ambiguity cessation of training and deconditioning will allow 
distinction to be made, since in the physiologic variant the 
hypertrophy decreases relatively rapidly once training is 
stopped, while in HCM it persists. In ambiguous cases, genotype 
analysis may be invaluable if there is detection of a specific 
disease-causing mutation.
Recommendations for qualification to participate in
competitive athletics
European and U.S authorities have issued recommendations 
(10,12) for competitive sport participation in athletes with HCM. 
Due to the scarcity of supporting clinical data, these 
recommendations are mainly based on the expert opinion of 
both groups. In athletes with a definitive diagnosis of HCM, both 
documents recommend the exclusion from most competitive 
sports, with the possible exception of low dynamic and low 
static sports (golf, billiards, bowling, cricket, and marksmanship) 
in those individuals considered to be at low risk for SCD. The 
groups differ in their recommendations regarding the genotype 
positive-phenotype negative athletes. The U.S. guidelines do not 
recommend exclusion of these individuals from competition due 
to the lack of data and unknown natural history. On the other 
hand, the ESC consensus document excludes these individuals 
from competitive sports and recommends amateur and leisure 
sport activities (10-12).
An agreement between the guidelines is that the implantation 
of a defibrillator, presence of a free-standing automated external
defibrillator, pharmacologic or surgical therapy or degree of 
phenotypic expression of the disease do not alter the 
aforementioned recommendations of either panel of experts.
Arrhythmogenic Right Ventricular Cardiomyopathy
Arrhythmogenic right ventricular cardiomyopathy is an 
inherited cardiac disorder characterized morphologically by 
myocyte death with subsequent fibro-fatty tissue replacement in 
the right ventricle (RV); and clinically by life-threatening 
arrhythmias and heart failure. ARVC can be inherited as an 
autosomal dominant or recessive trait. This disease may be 
segmental or diffuse. Involvement of the LV is frequently seen
(13). Mutations in the genes coding for components of the 
desmosomes have been recently recognized as the cause of 
ARVC. The genes affected by ARVC-causing mutations include 
those coding for plakoglobin, desmoplakin, plakophilin, 
desmoglein, desmocollin. The defects in the desmosomes, 
which are the intercellular junctions that anchor intermediate 
filaments to the cytoplasmic membrane in adjacent cells, cause 
myocyte detachment and death. Subsequently these myocytes 
are replaced by fibro-fatty tissue.
The prevalence of ARVC is estimated to be approximately
0.02% to 0.1% in the general population, with mortality rates 
range from 4% to 20% noted in major studies (14,15). ARVC is the 
leading cause of sports related deaths in Veneto region of Italy, 
accounting for 22% of SCD in young athletes, while in the U.S. it 
is associated with 4% of deaths.
Clinical presentation
The pre-clinical detection of ARVC in young competitive 
athletes is difficult, and the first manifestation is often SCD. The 
possibility of ARVC should be entertained whenever a young 
patient presents with syncope of unexplained cause, cardiac 
arrest, ventricular arrhythmias, and heart failure. As ARVC is a 
familial disorder, a history of SCD, syncope or ventricular 
arrhythmias in close relatives can be elicited. Diagnostic criteria 
for ARVC have been previously established (16). To qualify as 
ARVC, a patient must demonstrate either two major criteria, one 
major criterion plus two minor criteria, or four minor criteria. 
Criteria include RV structural or functional abnormalities, tissue 
characterization, ECG depolarization/conduction abnormalities, 
arrhythmias, and family history.
Electrocardiographic abnormalities include abnormalities 
such as T wave inversions in V1 to V3 in the absence of a right 
bundle branch block (RBBB), complete or incomplete RBBB. 
These findings are seen in 54% and 15% of the cases respectively. 
Prolongation of the QRS in leads V1 to V3 compared with lead V6 
is one of the major criterions and is satisfied if the QRS duration 
in leads V1 to V3 is 50 ms above the QRS duration in lead V6 in 
the presence of RBBB. Epsilon waves, small amplitude electrical 
potentials that occur at the end of the QRS complex, are another 
major diagnostic criterion found in up to 30% of cases of ARVC 
and represent delayed RV activation. Although not a sensitive 
finding, epsilon waves are highly specific for ARVC. When 
ventricular tachycardia (VT) occurs, it typically has left bundle 
branch block morphology, reflecting its right sided origin.
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Imaging characteristics
The most common echocardiographic findings are RV 
dilatation and severe hypokinesis. The abnormalities can range 
from mild regional RV dysfunction and dilatation, including 
aneurysm formation- to overt and severe RV dilatation and 
dysfunction (17,18). A ratio of the RVto LV end diastolic diameter 
>0.5 has a sensitivity of 86% and a specificity of 93%, with a 
positive predictive value of 86% and negative predictive value of 
93% for the diagnosis of ARVC (19). Patients suspected of ARVC 
should also undergo CMR imaging, which offers tissue 
characterization as well as detailed information on cardiac 
structure and function.
Recommendations for qualification to participate in
competitive athletics
Because of the risk of sudden death in patients with ARVC, 
patients with this condition should be prohibited from vigorous 
athletic competition. This prohibition remains in effect even 
after the subjects have received effective treatment such as 
implantable cardioverter defibrillator (ICD) placement because 
athletic competition may induce incessant ventricular fibrillation 
that cannot be terminated, given the response patterns of 
current devices (10-12). Moreover, ICD devices, particularly the 
vulnerable leads, may be damaged by athletics.
Long QT syndrome
Hereditary long QT syndrome (LQTS) is a genetic 
channelopathy with variable penetrance and clinical course. 
Clinically, it is characterized by an abnormal QT interval 
prolongation on the ECG and increased predisposition to 
syncope, polymorphous VT and SCD. It can be inherited as an 
autosomal dominant or recessive form. The QT prolongation is 
the result of delayed repolarization due to either a decrease in 
repolarizing potassium currents or late entry of sodium into the 
myocyte. Since it was first described by Jervell in 1957 (20), 
mutations in several genes that codify different subunits of 
potassium and sodium channels have been discovered. The 
most commonly involved genes are KCNQ1 (LQT1), KCNH2 
(LQT2), SCN5A (LQT3), mink (LQT5) and MiRPI (LQT6) (21).
The estimated prevalence of this disorder is in the range of 
1:5000 in the general population. Data from the registry of the 
Minneapolis Heart Foundation indicates that LQTS accounts for 
approximately 0.8% of the total deaths in young athletes (22). Ion 
channelopathies in general account for 3% of total deaths in 
young athletes in United States (3). The Italian pre-participation 
screening program reported a disqualification rate for Long QT 
syndrome of 0.69% of all athletes, based solely on the 
identification of a prolonged QT segment. A study conducted in 
United Kingdom, involving 2000 young athletes showed a 
prevalence of an isolated long QT interval of 0.4% (7 athletes). Of 
these 7 athletes, 2 had a high probability of LQTS based 
Schwartz LQT diagnosis scoring system and one carried a 
disease causing mutation, making a prevalence of diagnosed 
LQTS in young athletes of 0.15% (23).
Clinical presentation
The most common presentations include syncope, SCD or 
malignant ventricular arrhythmia in a young adult. Obtaining a 
detailed family history is essential given that it may reveal 
episodes of syncope or SCD, not only in first degree relatives but 
also in remote relatives. A personal or family history of deafness 
can also suggest the possibility of concomitant LQTS.
Electrocardiographic characteristics
A prolonged QT corrected for heart rate (QTc) identified in 
the absence of secondary causes of QT prolongation can make 
the diagnosis of LQTS. Males with a QTc >440ms or females with 
a QTc >460ms are considered to have an abnormally prolonged 
QT. The Bethesda #36 consensus document defines a prolonged 
QTc as an interval exceeding 470ms in males and 480 ms in 
females. A scoring system, based on personal and family history 
as well as ECG, has been developed for those cases where the 
diagnosis is not clear (24). Holter monitoring and exercise 
testing can help to improve diagnostic accuracy in unclear 
cases.
Recommendations for qualification to participate in
competitive athletics
The ESC consensus document recommends exclusion of the 
athlete with definitive diagnosis of LQTS from any type of 
competitive sports, while those asymptomatic genotype-positive, 
phenotype-negative athletes are discouraged from participation 
in competitive sports. The Bethesda conference #36 document 
also recommends exclusion of most competitive sports of those 
individuals with definitive diagnosis of LQTS, except from low 
dynamic and low static sports. Unlike the ESC, these guidelines 
allow participation in competition of genotype-positive, 
phenotype-negative athletes, with special consideration of 
individuals with LQT1 mutation. Due to the strong association 
between swimming deaths and LQT1 mutation, these genotype- 
positive, phenotype-negative athletes should refrain from 
competitive swimming (10, 25).
Brugada syndrome
Brugada syndrome (BS) is an autosomal dominant inherited 
channelopathy with variable pathophysiology and clinical 
expression. This syndrome as described initially by Brugada & 
Brugada is characterized by a right bundle branch block pattern, 
persistent ST segment elevation, and sudden cardiac death (26). 
Mutations in chromosome 3, specifically the gene encoding the 
alpha subunit of the cardiac sodium channel, SCN5A, are 
responsible for this syndrome. The ST segment elevation seen in 
BS is probably caused by the selective loss of the action 
potential dome in the right ventricular epicardium, sparing the 
endocardium (26). The predisposition to develop malignant 
ventricular arrhythmias is caused by the electrical heterogeneity 
within the RV epicardium, leading to closely coupled premature 
ventricular contractions via a phase 2 reentrant mechanism.
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Clinical presentation
Brugada syndrome is 8 to 10 times more prevalent m men 
than in women (28). The typical presentation is syncope, SCD or
ventricular arrhythmias in a young adult. Malignant ventricular
arrhythmias or SCD typically occur at rest and often at night, as
a consequence of increased vagal tone and/or withdrawal of
sympathetic activity. This presentation in conjunction to the
electrocardiographic findings of RBBB pattern and ST segment
elevations in right sided precordial leads can make the diagnosis
of BS. In those patients where the diagnosis of BS is not clear,
diagnostic criteria have been developed by the European
Society of Cardiology as noted below (29).
Electrocardiographic characteristics
Three different electrocardiographic patterns of BS have 
been recognized (See the ECG patterns in the article of Khan A 
et al of this supplement). In Brugada type 1, the QRS complex 
ends with a prominent J point, followed by an elevated down­
sloping ST segment (coved type or dome shape) and a negative 
T wave with a normal QT interval. Leads V, to V3 show the most 
prominent changes, with the degree of ST segment elevation 
tapering off in adjacent leads. It is a characteristic finding that 
the ST segment elevation in the right precordial leads is not 
accompanied by reciprocal ST segment depression in opposite 
leads. In Brugada type 2 and 3, the ST segment has a saddle­
back shape. The ST segment descends to the baseline and then 
rises to a biphasic or monophasic T wave. If the ST segment is 
elevated >1mm is classified as BS type 2, otherwise as BS type
3. The presence of ST segment elevation in right precordial 
leads in the absence of secondary causes is called idiopathic ST 
segment elevation a definitive diagnosis of BS should be 
pursued with genetic testing.
Recommendations for qualification for participation in
competitive athletics
Ion channelopathies as a group are responsible for 3% of 
total deaths in young athletes in United States (3). The 
contribution of BS to these deaths is not well defined. Although 
no association between SCD or malignant ventricular 
arrhythmias due to BS and exercise has been established, the 
general consensus in Europe and U.S. recommends exclusion of 
young athletes from competition. These recommendations are 
based on the theoretical consideration that increased vagal 
tone, resulting from athletic conditioning could potentially 
increase the risk of malignant ventricular arrhythmias and SCD 
at rest or even post exercise. The potential impact of hyperthermia 
caused by exercise, which very often unmasks the 
electrocardiographic manifestations of BS, further supports the 
recommendation of both panel of experts (10, 25).
Catecholaminergic polymorphic ventricular tachycardia
Catecholaminergic polymorphic ventricular tachycardia 
(CPVT) is an autosomal dominant and recessive inherited 
disorder characterized by bidirectional and polymorphic 
ventricular tachycardia in response to vigorous exercise or
intense emotional stress, in the absence of identifiable precipitant 
factors. It is an important cause of SCD in children and young 
adults. The cumulative cardiac mortality is 31% by the age of 30 
years (30). Pathogenic mutations have been identified in the 
genes encoding the ryanodine receptor 2 (chromosome 1q42- 
q43) and calsequestrin 2 (31). Both genes are involved with the 
release and handling of intracellular calcium. A proposed 
mechanism for the development of malignant ventricular 
arrhythmias is that extrasystolic activity, induced by delayed 
afterdepolarization, triggers catecholamine-induced VT. 
Dispersion of transmural depolarization by the extrasystolic 
activity is the nidus for the development of reentrant 
tachyarrhythmias (32).
Clinical presentation and electrocardiographic characteristics
The most common presentations of CPVT include recurrent 
syncope (79%), cardiac arrest (7%) and family history of SCD 
(14%) (33). These typically present during childhood or early 
adulthood as polymorphic VT in the absence of structural or 
other functional causes and are precipitated by exercise or 
emotional stress.
The electrocardiogram will reveal polymorphic ventricular 
arrhythmias; including isolated premature ventricular 
contractions that can progress to bigeminy, multifocal premature 
ventricular complexes and polymorphic ventriculartachycardia, 
that can degenerate in ventricular fibrillation. The most common 
form of CPVT is non-sustained VT (72%), followed by sustained 
VT (21%) and ventricular fibrillation (7%). The morphology of 
CPVT can be polymorphic (62%), polymorphic and bidirectional 
(21%), bidirectional (10%), or polymorphic with ventricular 
fibrillation (7%) (29). Typically these arrhythmias can be induced 
by exercise or catecholamine infusion.
Recommendations for qualification to participate in
competitive athletics
The consensus is that individuals with a definitive diagnosis 
of CPVT, as well as genotype-positive athletes with evidence of 
exercise or pharmacologic induced VT, should be excluded from 
competitive sports. Similar to LQT1, athletes with a diagnosis of 
CPVT should be excluded from competitive swimming. The 
Bethesda #36 document leaves open the possibility in these 
individuals of practicing minimal contact, low dynamic, static 
activities. Furthermore, this document does not restrict the 
participation in competitive sports of asymptomatic, genotype- 
positive, phenotype-negative individuals without evidence of 
isoproterenol-induced VT (10, 25).
Summary
Inherited cardiac disorders are responsible for the majority of 
sudden cardiac deaths in young competitive athletes. These 
conditions have been well described allowing accurate diagnosis 
for most patients. Perhaps more important is formal structure that 
allows for these diagnoses to be made, especially for those 
young patients who plan to participate in vigorous exercise or
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competitive athletics. Key to successful prevention of SCD in 
athletes are guidelines that mandate a screening protocol that 
has both acceptable sensitivity and specificity to detect those at 
risk for SCD. While European guidelines have embraced 
performance of an ECG, in addition to expanded family, personal 
history, and physical examination, guidelines in the United States 
have not embraced use of the ECG for reasons discussed earlier 
in this review. The debate will likely continue until further 
research provides us with information on what characteristics in 
the ECG should be used to determine need for disqualification 
and further cardiac testing.
Although, subtle differences may exist between the current 
U.S. and European recommendations, young athletes with a 
definitive diagnosis of HCM, ARVD or any of the ion 
channelopathies discussed here should be advised against 
participation in competitive athletics. A grey zone exists in the 
case of genotype-positive, phenotype-negative individuals, 
where the paucity of experimental and clinical evidence limits 
our capacity to provide recommendations against or in favor of 
participation. In this last group, recommendations should be 
individualized, taking in consideration the risk of sudden cardiac 
death based on the individual's risk factors. A close physician- 
patient relationship should be established to assure that the 
specific recommendations as to type and intensity of athletic 
involvement are well understood and adequately discussed. For 
minors parental discussion is vital as well.
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